About

The Parkinson’s Pioneer Fund focuses on investing in debt and equity instruments globally to develop drug treatments for Parkinson’s disease and related neurological conditions. It targets seed and early-stage biotech companies, bridging the gap between startups and scalable drug solutions. In collaboration with the Parkinson’s Virtual Biotech, it aims to foster scientific innovation, leveraging the most recent research and technologies in the field.

With a 10-15 year investment horizon, it aims to use deep expertise for pragmatic capital deployment in high-risk investments, contributing to advancements in drug discover and treatment efficacy.

Core Principles

FOCUSSED COLLABORATION

Championing private capital and public/philanthropic organisation partnerships which harness collective knowledge, resources and insights to seek the best opportunities for win-win outcomes.

INNOVATION

Embedding cutting-edge scientific and clinical expertise with ground-breaking research will unlock significant diversified opportunities globally for pioneer investment.

GOVERNANCE

Expert knowledge, robust governance, and transparent relationships whilst prioritising the highest integrity and ethical standards are essential components of our investment strategy.

SUSTAINABLE IMPACT

New capital will accelerate breakthrough therapies which have the greatest potential for positive commercial, economic and social impact over the long term.